Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BMS-986517 + BNT327 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BMS-986517 | BMS 986517|BMS986517 | Limited information is currently available on BMS-986517 (Sep 2025). | ||
| BNT327 | PM8002|Pumitamig|BNT-327|BNT 327|BM-8002 | PD-L1/PD-1 antibody 138 VEGFA Antibody 6 | BNT327 (PM8002) is a bispecific antibody that targets VEGFA and PD-L1 (CD274), which potentially induces antitumor activity (J Clin Oncol 42, no. 16_suppl (May 29, 2024) 5524). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07160725 | Phase Ib/II | BMS-986517 + BNT327 BMS-986517 | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | Recruiting | USA | ESP | DNK | 1 |